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Because of its enhanced activation of plasminogen in
association with fibrin compared with free plasminogen,
tissue-type plasminogen activat or (t-PA) evoked excite-
ment as a potentially useful pharmacologic activator of
the fibrinolytic system. Initial studies in experimental
animals and patients demonstrated that it induced coro-
nary thrombolysis rapidly and without concomitant,
marked fibrinogenolysis in contrast tostreptokinase. Large
scale clinical trials soon followed. Their results indicate
that intravenous administration of topA produced hy
Fibrinolysis has bee n recognized for more than 200 years ,
Perhaps surprisingly , coronary thrombolysis has a relative ly
long history as well , The current intense interest in this
mode of treatment of acute myocardial infarc tion reflects.
in part . improved end points of efficacy (co ronary angio-
gra ms that ca n be acquired safe ly in critically ill pat ients),
increased appreciation of the seminal roles of thrombo sis in
the etio logy of transmural myocardial infarction and reper-
fusion in the salvage of jeopardized tissue and the avail-
abil ity of activators of the fibrinolytic system with relative
clot selectivity such as tissue-type plasminogen activator (t-
PAl only recently synthesized successfully in pharmaceu-
tical quantities by recombinant DNA technology (rt-PA ).
Because of the relative clot selectivity oft-PA , a property
reflecting its higher affinity for plasminogen in the fibrin
domai n than for circulating , free plasminogen , we evaluated
human t-PA and subsequently rt-PA in ex perimental an imals
and patients with coro nary thrombosi s (1-5) . Clot lysis was
elicited promptl y without marked fibrinoge nopenia or in-
duction of a sys temic lytic state pred isposing to bleedin g,
Subseq uently. seve ral large sca le clinica l trials were un-
dertake n with rl-PA (6-10). Some of their results are the
subjec t of this brief status report . Because this material
addre sses not only publ ished results but also work in prog-
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recombinant DNA technology (rt-Pa ) elicits coronary
thromboly sis in two-thirds or more of treated patients
with angiographically documented thrombotic occlu-
sions generally without perturhing hemostatic mecha-
nisms or inducing marked fibrinogenolysis. Bleeding is
usually confined to vascular access sites and episodes of
major bleeding are rare. Overall 6 week survival for
treated patients with documented acute myocardial in-
farction may be as high as 95%.
(J J1m Coli Cardiol 1987;10:40B-4B)
ress, some of the data are cited as personal communications
provided by inves tigators before completion of manuscript s
already being prepared , including mater ial compiled by Drs.
Chesebro , Grossbard , Mueller and Passa mani.
The TIMl Trials
Phase I. The Thrombolysis in Myocardial Infarction
(TIM!) trial conducted by the National Heart, Lung, and
Blood Institute (NHLBI) has evo lved through several phases
to date. One (Phase I) docum en ted an almos t twofold greater
incidence (62 compared with 31% ) of angiographically con-
finne d coro nary thromb olysis with rt-PA compared with
streptokinase in a double-blind , prospect ive . random selec-
tion desig n (Fig. I) ( I I) . Significant but modest improve-
ment of global and regional ventricular function has been
evide nt in TIMI trial patients in whom reperfusion was
induced by rl-PA within 4 hours of the onset of ches t pain
(12.1 3).
Mueller and her colleagues (14) delineated the incidence
of bleeding in several phases of the TlAlI trial to date (FiX.
2) . The incidence of bleeding with streptokinase and rt-PA,
the two activators used in Phase I, was similar. For rt-PA
in all the phases of the TIMI tria l analyzed by Mueller et
a!. bleedi ng was confined largely to vasc ular access sites
(Fig. 3) . Bleed ing with rt-PA was generally but only loosely
related to the magnitude of decreased fibrinogen and in-
creased fibrinogen degr adation products. Nevertheless , the
associations support the view that laboratory criteria of a
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however, based in part on data from several studies and
with information obtained from computer-assisted analysis
of pharmacodynamics (17), that consumption of alpha-.
antiplasmin indicative of risk occurs with doses and dura-
tions of infusion of rt-PA exceeding theoretically defined
limits. Accordingly, the TIMI investigators and the TIMI
policy board monitored each upen label phase of the trial
Figure 2. TIMI trial (total number = S50), Incidence of bleeding
expressedas the percentof patientsstudiedin thedesignatedphases
of the TIMl trial categorizedas major, intracranial or total number
of episodes whether minor or major. The percentof patients man-
ifesting each type of episode in each of the phases specified in the
trial is shown. Results in patients treated with streptokinase (SK)
in Phase I are shown in the lowest section of the figure (n =
147). Those in patients treated with recombinant tissue-type plas-
minogen activator (rt-PAj in Phase I (n = 143) arc represented
by the bars immediately above. In open label phases A through
E, all patients were treated with J1-PA but different doses were
employed, The dose of rt~PA in Phase I was 80 mg over 3 hours
(40. 20 and 20 mg/h, respectively). An identical dose of rt-PA
prepared by a different production procedure in which a larger
proportion of the product comprised material that had not been
cleaved by plasmin (so-calledsinglechain rt-PA) was usedin open
label phase A (n = 48). Because recanalization rates appear to
be lower on a mg/rng basis with material produced by the newer
procedures. the dose was increased to 100 rng over 3 hours (60,
20 and 20 rng/h, respectively) for open label phase B (n = 88),
It was increased further to 150 mg over 6 hours (90,20, 10, 10.
10 and 10 rng/h, respectively) for open label phase C. In each of
these phases. infusions of rt-PA were initiated only after angio-
graphic demonstration of coronary occlusion had been acquired.
Subsequentopen label phases of the TIMI trial employed admin-
istration of rt-PA without an initial angiogram and with the first
angiogram performed IR to 4R hours (phase D, n = 42) or either
2 hours or 18 to 48 hours (phase E) after the onset of administra-
tion of rt-PA in a total dose of 150 mg over 6 hours
(n = 317), Because phase E was performed in an open label
fashion with vigorous surveillance of possible bleeding compli-
cations in light of what was recognized to be a very high dose of
rt-PA. 53 of the 317 patients were treated in this phase after an
adjustment had been made to a lower dose (100 rng over 6 hours;
60,20,5,5,5 and 5 mg/h, respectively) on October 21. 1986.
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systemic lytic state portend an increased risk of bleeding,
Accordingly, the systemic lytic state seen invariably with
even subtherapeutic doses uf conventional activators is not
likely to be entirely benign.
Compared with streptokinase, rt-PA lowers plasma fi-
brinogen markedly less judging from results in subsets of
patients with extensive laboratory data analyzed in detail in
both TIMI Phase I (data not shown) and the European Co-
operative Trial (Fig. 4) (15). Major bleeding requiring trans-
fusion occurs less frequently with rt-PA than with strepto-
kinase, judging from results in the European Cooperative
Trial (Fig. 5) (10,15).
Open label phases. Several open label phases of TIMI
were undertaken in part to delineate optimal dose and du-
ration of treatment with the originally produced rt-PA and
with material available subsequently that comprised a larger
fraction of so-called single chain (suspension-culture, non-
plasmin split) rt-PA, Despite some fluctuation of incidence,
major bleeding occurred within a range of 7 to 25% with
dose regimens that varied from 80 mg over 3 hours to 150
mg over 6 hours, Attempts to identify the upper bounds of
safe dosage were motivated in part by the higher earlier
recanalization rates (42 compared with 13% after 30 min-
utes) when 90 as opposed to 40 mg of rt-PA was given in
the first hour. Furthermore, the higher doses of rt-PA used
in TIMI open label phase E compared with those used in
Phase I were associated with substantially higher rates of
patency early (2 hours) and later ( IR to 4R hours) after the
onset of infusion (Fig, 6) (16). It was well recognized,
Figure 1. TIMl phaseI-efficacy. Patency ratesfor patients treated
with recombinant tissue-type plasminogen activator (rt-PA) (80
mg over 3 hours)or streptokinase (SK) (1.5 million U over I hour)
in the double-blind, random patient selection, prospective study
comprising Phase I of the TIMI trial. The number of subjects in
the two groups was 113 and 119, respectively. rt-PA was more
effective than streptokinase whetherrecanalization was defined by
angiography 30 (hatched bars) or 90 (solid bars) minutes after
the onset of administration of the active thrombolytic agent.
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Figure 5. Hemorrhagic events within 4l:\ hours after infusion of
recombinant tissue-type plasminogen activator (rl-PA) (0.75mg/kg
over 90 minutes) or streptokinase (SK ) (1.5 million U over 60
minutes) in patients studied by Verstraete et al. (10) in the Eu-
ropean Cooperative Trial. Both the incidence of major bleeding
and the overall incidence of bleeding were less among patients
treated with fl-PA.
Figure 6. Patency rates. Comparison of infarc t-re lated coronary
artery patency evident angiographically 90 minutes after the onset
of infusion of recombinant tissue-type plasminogen activator (rt-
PAl in 429 patients with initially occluded coronary arteries doc-
umented by preinterventional angiography in Phase I (40, 20 and
20 mg of I-PA infused over 3 hours) and 2 hours or 18 to 48 hours
after the onset of infusion or rt-PA. to patients without preinter-
ventional angiography but with criteria of evolving transmural
myocardial infarction fulfilling the TIMI entry criteria in open label
phase E of the TIMI trial (90 mg of rt-PA given in the first hour).
Results in both groups (Phase I and phase E) are compared with
the incidence of patency evident in preinterventional angiograms
available for the Phase I patients only. The higher doses of rt·PA
used in open label phase E compared with those used in Phase I
were associated with a somewhat greater rate of early patency.
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Figure 3. Compilation of bleeding episodes in 344 patients studied
in TIMI Phases I . A. 8 and C. Most episodes of bleeding were
associated with vascular access sites. Additional information per-
tinent to bleeding in specific phases oft he TIMI trial and to specific
dose regimens particularly with respect to intracranial bleeding is
summarized in Ref, I ~. As noted in that communication, a 1.6%
incidence rate of intrac ranial bleeding (5 of 311 patients) occurred
among patients treated with 150 mg. In view of this experience,
the dose was reduced to 100 mg for patients treated subsequently
in the TIMI trial. In the remaining 53 patients studied in TIMI
open label phase E who were treated with the 100 mg dose, no
intracranial bleeding occurred. Cath ~ catheterization site: GI =
gastrointestinal tract site.
rigorously and elected to reduce the maximal dose tested
(150 mg ove r 6 hours) to 100 mg given ove r 6 hours based
on experience with 311 patients in open label phase E ( 18) .
This decision was reinforced by [he lack of a detectable
decrea se of efficacy (reca nalization rate for infarct-related
PHA S E I OP E N L ABE L E
Figure 4. Hbr iuogenclysis (after Collen et al. [151J. Changes in
plasma fibrinogen after I hour expressed as a percent of control
values with data obtained with either a precipitation (sulfite) (solid
bars) or kinetic (st r jped bars) assay after 60 minutes of treatment
with recombinant tissue-type plasminogen activator (rt -Pa) , strep-
tokinase (SK) or neither agent (control) in 131 patients with acute
myocardial infarction. The number of patients in each group is
indicated in parentheses. Patients evaluated were among those
studied in the European Cooperative Trial (10.15).
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Figure7. Mortality and morbidity throughout the hospital course
and throuehouta 6 week interval of fol low-upamong 31 7 patients
treated with recombinant tissue-type plasminogenactivator ([(- PA)
in open label phase E of the TIMI trial us well as the incidence
of recurrent myocardial infarction (MI) or extension of infarction
during both intervals. Episodes of intracranial bleeding (lC> were
included in the tabulation as deaths. Even with the classification
of such bleeding episodes as " mortality," survival throughout the
hospital course and throughout a 6 week inrerval of follow-upafter
infusion of rt-PA was unusually high (94'k) for patients with doc-
umented acute transmural myocardial infarction.
arteries) with the 100 mg compared with the 150 mg dose
of n-PA over 6 hours and the virtual absence of intracranial
bleeding in patients treated with the 100 mg dose to date.
Among 400 patients treated with 120 to 170 mg of rt-
PA over intervals comparable with those employed in TIMI
open label E and studied in clinical trials monitored by the
Gcnentech Corporation. the incidence of intracranial bleed-
ing within48 hours of infusion of rt-PA was < 0.5%. Among
99R patients treated with equipotent regimens of rt-PA
produced by diverse production modes over the past several
years it was only 0.3% (19), Among analogous trials con-
ducted in Europe involving 7H 1 patients it was 0.26% (E.
Grossbard , personal communication).
Th erapeutic failures. When intracranial bleeding and
death are considered together a~ criteria of failure of therapy
with rt-PA, only 5% of 317 patients given 150 mg of rt -
PA were adjudged to have had therapeutic failure throughout
their entire hospitalization in open label phase E of the TIMI
trial. Only 6% were adjudged to have had therapeutic failure
throughout a 6 week interval 01" follow-up (Fig. 7) (E. Pas-
sumani. personal communication), Patency occurred in 87lif
of 220 patients. judging from results of angiography 18 to
48 hours after treatment. When the dose regimen in open
label phase E was modified to 100 mg 01" rt-PA over 6 hours.
efficacy remained apparently constant. The incidence of
intracranial bleeding at this dose has been low (none among
the 53 patients treated with 100 mg in open label phase E).
Assi' lance in the preparation or the typescript hy Lori Dales i.,appreciated.
End point results to date from the two largest prospective.
randomized patient assignment. double-blind trials with rt-
PA (the TIMI trial and the European Cooperative Trial) are
concordant and compatible with those of smaller studies
with native t-PA and rt-PA as well as with those of studies
of rt-PA combined with angioplasty (20- 22). In concert.
the data indicate that: I ) lntruvenous rt-PA elicits recanal-
ization promptly in >70% or patients-a success rate com-
parable with that documented with maximal doses of intra-
coronary streptokinase: 2) It-PA depletescirculating fi brinogen
and elevates circulating fi brinogen degradation products much
less than does streptokinase. as reflected by results of pro-
spective, randomized, clinical trials (1 5.23); 3) bleeding
associated with administration of rt-PA under research pro-
tocol conditions generally involving large doses of heparin
concomitantly is confined generally to vascular access sites
and is readily manageable; and 4) early treatment with rt-
PA is associated with remarkably low hospital and 6 week
mortality among patients with documented acute transmural
myocardial infarction.
Conclusions
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